223 related articles for article (PubMed ID: 21400475)
1. The anti-CD20 antibody rituximab reduces the Th17 cell response.
van de Veerdonk FL; Lauwerys B; Marijnissen RJ; Timmermans K; Di Padova F; Koenders MI; Gutierrez-Roelens I; Durez P; Netea MG; van der Meer JW; van den Berg WB; Joosten LA
Arthritis Rheum; 2011 Jun; 63(6):1507-16. PubMed ID: 21400475
[TBL] [Abstract][Full Text] [Related]
2. IL-40: A New B Cell-Associated Cytokine Up-Regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates With Disease Activity, Autoantibodies, and NETosis.
Navrátilová A; Andrés Cerezo L; Hulejová H; Bečvář V; Tomčík M; Komarc M; Veigl D; Tegzová D; Závada J; Olejárová M; Pavelka K; Vencovský J; Šenolt L
Front Immunol; 2021; 12():745523. PubMed ID: 34745117
[TBL] [Abstract][Full Text] [Related]
3. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results.
Kavanaugh A; Rosengren S; Lee SJ; Hammaker D; Firestein GS; Kalunian K; Wei N; Boyle DL
Ann Rheum Dis; 2008 Mar; 67(3):402-8. PubMed ID: 17644541
[TBL] [Abstract][Full Text] [Related]
4. Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy.
McGovern JL; Nguyen DX; Notley CA; Mauri C; Isenberg DA; Ehrenstein MR
Arthritis Rheum; 2012 Oct; 64(10):3129-38. PubMed ID: 22674488
[TBL] [Abstract][Full Text] [Related]
5. TNFα promotes Th17 cell differentiation through IL-6 and IL-1β produced by monocytes in rheumatoid arthritis.
Zheng Y; Sun L; Jiang T; Zhang D; He D; Nie H
J Immunol Res; 2014; 2014():385352. PubMed ID: 25436214
[TBL] [Abstract][Full Text] [Related]
6. Modulation of STAT-3 in rheumatoid synovial T cells suppresses Th17 differentiation and increases the proportion of Treg cells.
Ju JH; Heo YJ; Cho ML; Jhun JY; Park JS; Lee SY; Oh HJ; Moon SJ; Kwok SK; Park KS; Park SH; Kim HY
Arthritis Rheum; 2012 Nov; 64(11):3543-52. PubMed ID: 22736176
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
[TBL] [Abstract][Full Text] [Related]
8. [1,25(OH)2-Vitamin-D3 attenuates Th17-related cytokines expression in peripheral blood mononuclear cells in patients with early-diagnosed rheumatoid arthritis].
Wen H; Luo J; Zhang X; Zhang C; Zhao X; Wang X; Li X
Zhonghua Nei Ke Za Zhi; 2015 Apr; 54(4):317-21. PubMed ID: 26268060
[TBL] [Abstract][Full Text] [Related]
9. Rheumatoid arthritis patients exhibit impaired Candida albicans-specific Th17 responses.
Bishu S; Su EW; Wilkerson ER; Reckley KA; Jones DM; McGeachy MJ; Gaffen SL; Levesque MC
Arthritis Res Ther; 2014 Feb; 16(1):R50. PubMed ID: 24513269
[TBL] [Abstract][Full Text] [Related]
10. IL-17/Th17 mediated synovial inflammation is IL-22 independent.
van Hamburg JP; Corneth OB; Paulissen SM; Davelaar N; Asmawidjaja PS; Mus AM; Lubberts E
Ann Rheum Dis; 2013 Oct; 72(10):1700-7. PubMed ID: 23328939
[TBL] [Abstract][Full Text] [Related]
11. Rheumatoid synovial fluid interleukin-17-producing CD4 T cells have abundant tumor necrosis factor-alpha co-expression, but little interleukin-22 and interleukin-23R expression.
Church LD; Filer AD; Hidalgo E; Howlett KA; Thomas AM; Rapecki S; Scheel-Toellner D; Buckley CD; Raza K
Arthritis Res Ther; 2010; 12(5):R184. PubMed ID: 20929536
[TBL] [Abstract][Full Text] [Related]
12. CD20 antigen imaging with ¹²⁴I-rituximab PET/CT in patients with rheumatoid arthritis.
Tran L; Huitema AD; van Rijswijk MH; Dinant HJ; Baars JW; Beijnen JH; Vogel WV
Hum Antibodies; 2011; 20(1-2):29-35. PubMed ID: 21558621
[TBL] [Abstract][Full Text] [Related]
13. Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway.
Alzabin S; Abraham SM; Taher TE; Palfreeman A; Hull D; McNamee K; Jawad A; Pathan E; Kinderlerer A; Taylor PC; Williams R; Mageed R
Ann Rheum Dis; 2012 Oct; 71(10):1741-8. PubMed ID: 22550316
[TBL] [Abstract][Full Text] [Related]
14. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.
Teng YK; Levarht EW; Toes RE; Huizinga TW; van Laar JM
Ann Rheum Dis; 2009 Jun; 68(6):1011-6. PubMed ID: 18647852
[TBL] [Abstract][Full Text] [Related]
15. B-cell therapies for rheumatoid arthritis.
Scher JU
Bull NYU Hosp Jt Dis; 2012; 70(3):200-3. PubMed ID: 23259629
[TBL] [Abstract][Full Text] [Related]
16. TNF blockade requires 1,25(OH)2D3 to control human Th17-mediated synovial inflammation.
van Hamburg JP; Asmawidjaja PS; Davelaar N; Mus AM; Cornelissen F; van Leeuwen JP; Hazes JM; Dolhain RJ; Bakx PA; Colin EM; Lubberts E
Ann Rheum Dis; 2012 Apr; 71(4):606-12. PubMed ID: 22219138
[TBL] [Abstract][Full Text] [Related]
17. IL-25 attenuates rheumatoid arthritis through suppression of Th17 immune responses in an IL-13-dependent manner.
Liu D; Cao T; Wang N; Liu C; Ma N; Tu R; Min X
Sci Rep; 2016 Nov; 6():36002. PubMed ID: 27812008
[TBL] [Abstract][Full Text] [Related]
18. [The role of T helper 17 cells of synovial fluid in rheumatoid arthritis].
Lin H; Zhou YL; Li J; Li YJ; Zhao Y; Yan B; Liu Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Nov; 44(6):907-10. PubMed ID: 24490499
[TBL] [Abstract][Full Text] [Related]
19. B cell depletion treatment decreases Th17 cells in patients with rheumatoid arthritis.
Bounia CA; Liossis SC
Clin Immunol; 2021 Dec; 233():108877. PubMed ID: 34740842
[TBL] [Abstract][Full Text] [Related]
20. IL-37 Alleviates Rheumatoid Arthritis by Suppressing IL-17 and IL-17-Triggering Cytokine Production and Limiting Th17 Cell Proliferation.
Ye L; Jiang B; Deng J; Du J; Xiong W; Guan Y; Wen Z; Huang K; Huang Z
J Immunol; 2015 Jun; 194(11):5110-9. PubMed ID: 25917106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
